$BIIB has received 4 mentions from 2 distinct FinTwit voices over the past 12 months, with the first mention appearing on March 6, 2026. The biotech category dominated discussion, with @adamfeuerstein accounting for 3 of the 4 mentions and @jacobplieth contributing 1 mention. The most recent activity occurred on May 14, 2026.

Key topics discussed included Biogen's acquisition of Apellis for $5.6 billion announced on March 31, 2026, and developments regarding the company's tau-targeting Alzheimer's drug Diranersen (BIIB080). The May 14 discussion noted mixed results from a mid-stage study, with the drug reducing tau and slowing cognitive decline but failing to demonstrate a dose response as the primary endpoint, with full details expected at the AAIC meeting in July 2026.